Table 6 Analysis of treatment and follow-up of VTE patients
From: Clinical impact of the PAI-1 4G/5G polymorphism in Chinese patients with venous thromboembolism
Variables | n (%) |
|---|---|
Site of thrombosis (n = 89) | |
 Lower extremity DVT | 64 (71.9) |
 Upper extremity DVT | 5 (5.6) |
 PE | 5 (5.6) |
 Lower extremity DVT + PE | 6 (6.7) |
 Portal vein | 5 (5.6) |
 Othersa | 4 (4.5) |
Treatment (n = 89) | |
 Rivaroxaban | 39 (43.8) |
 Heparinb | 25 (28.1) |
 Warfarin | 19 (21.3) |
 Aescuven Forte | 11 (12.4) |
 Othersc | 17 (19.1) |
Therapeutic effect (n = 41) | |
 Complete recanalization | 13 (31.7) |
 Partial recanalization | 19 (46.3) |
 No recanalization | 9 (22.0) |
Recurrence status after recanalization (n = 32) | |
 Recurrence | 11 (34.4) |
 No recurrence | 21 (65.6) |